Clinical trial
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
NCT04007536 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
- Lead sponsor
- Denali Therapeutics Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 23, 2019
- Completion date
- March 1, 2024
- Enrollment
- 18 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.